Schedule 13G ownership disclosure

REIN THERAPEUTICS INC

Common Stock, $0.0001 par value per share · CUSIP: 00887A204

Event date: 2025-05-05

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOS FUND III, LP

    Shares: 430,665.00 · Class: 0.7%

  • BIOS FUND III QP, LP

    Shares: 2,801,953.00 · Class: 4.7%

  • BIOS FUND III NT, LP

    Shares: 450,811.00 · Class: 0.8%

  • BIOS EQUITY PARTNERS III, LP

    Shares: 3,683,429.00 · Class: 6.2%

  • CAVU MANAGEMENT, LP

    Shares: 3,683,429.00 · Class: 6.2%

  • BIOS CAPITAL MANAGEMENT, LP

    Shares: 3,683,429.00 · Class: 6.2%

  • CAVU ADVISORS, LLC

    Shares: 3,683,429.00 · Class: 6.2%

  • BIOS ADVISORS GP, LLC

    Shares: 3,683,429.00 · Class: 6.2%

  • LESLIE WAYNE KREIS, JR.

    Shares: 3,683,429.00 · Class: 6.2%

  • AARON GLENN LOUIS FLETCHER

    Shares: 3,683,429.00 · Class: 6.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-076281
Form type
SCHEDULE 13G
Filer
BIOS Fund III, LP
CIK
CIK 1791917
Filed
Aug 11, 2025
Reporting period
May 05, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub